Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Deregulation of Transcriptional Enhancers in Cancer.Cancers · 2021
   Review
2. Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer.Cancer cell · 2018
   Article
3. A novel EGFR-TKI inhibitor (cAMP-HOncotarget · 2017
   Article
4. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.Lung cancer (Amsterdam, Netherlands) · 2017
   Article
5. Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017
   Review

Corrections and comments

• Commented on by
  Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Response.2016
• Comment on
  Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.2015

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as